Govindan R, et al. Phase 1 study of safety, tolerability, PK and efficacy of AMG 510, a novel KRAS G12Cinhibitor, evaluated in NSCLC. Abstract OA02.02. WCLC 2019, 7-10 september, Barcelona, Spanje.
Synergetisch effect van radiotherapie + immuuntherapie bij NSCLC
mei 2021 | Immuuntherapie, Longoncologie, Radiotherapie